# Apothecary Pharma's compounded tirzepatide injections recalled nationwide, FDA cites sterility lapse

Attorney advertising. Brief by Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. Published 2026-10-20; updated 2026-10-20. Responsible attorney: Lou Schwartz. Canonical: https://www.snalawyers.com/insights/apothecary-pharma-s-compounded-tirzepatide-injections-recalled-nationw

The FDA has classified Apothecary Pharma LLC's voluntary nationwide recall of compounded tirzepatide injection vials, the active ingredient in Zepbound and Mounjaro, as a Class II recall due to a lack of assurance of sterility. The recall also covers one lot of the company's NAD+ injection. The FDA had sent Apothecary Pharma a warning letter in December 2025 citing serious deficiencies in its sterile drug manufacturing practices.

**Why it matters.** The recall adds to mounting FDA scrutiny of compounded GLP-1 products and could generate consumer injury and product-liability inquiries alongside other compounding-related litigation.

## Sources

1. [Becker's Hospital Review: Compounded GLP-1 injections recalled nationwide](https://www.beckershospitalreview.com/glp-1s/compounded-glp-1-injections-recalled-nationwide-4-notes/)
2. [Fox Business: GLP-1 injections recalled nationwide over sterility concerns](https://www.foxbusiness.com/healthcare/glp-1-injections-recalled-nationwide-over-sterility-concerns)

To ask the firm about this, use the intake assistant at https://www.snalawyers.com/insights/apothecary-pharma-s-compounded-tirzepatide-injections-recalled-nationw#ask. General information, not legal advice.